Rithim Biologics, Inc.

Rithim Biologics, Inc. is a biotechnology startup founded in March, 2016, with a mission "Toward a Normal Heart Rhythm." The company is focused on developing gene therapies to address tachycardias in humans, particularly targeting atrial fibrillation (AF) and post-operative AF (POAF) in patients undergoing cardiac surgery. The potential market for their therapies is significant, as POAF affects a large percentage of patients undergoing procedures such as coronary artery bypass graft (CABG) surgery and heart valve surgery, representing a substantial burden on healthcare systems. With the enormous potential market size and the critical unmet need in the treatment of tachycardias, Rithim Biologics is well-positioned to make a significant impact in the biotechnology industry. The application of gene therapies to address cardiac conditions represents a cutting-edge approach that has the potential to revolutionize the treatment of these prevalent cardiac conditions. However, as of the latest available information, there is no public record of any external investments or investors in Rithim Biologics. This may indicate that the company is either self-funded or in the early stages of seeking external investment. This presents potential opportunities for venture capital firms seeking to invest in groundbreaking biotechnology innovations. In summary, Rithim Biologics, Inc. is an early stage biotechnology startup with a compelling focus on gene therapies for tachycardias, particularly AF and POAF. The company's potential to address a significant healthcare burden and its innovative approach make it an intriguing prospect for venture capital investors looking to support pioneering advancements in the biotechnology sector.